Abstract
Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.
References
Sep 23, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H von der MaaseP F Conte
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Aug 5, 2004·British Journal of Cancer·S A HussainN D James
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CarlesUNKNOWN Spanish Oncology Genito Urinary Group Study Group
Mar 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jaafar BennounaLaurent Nguyen
Apr 28, 2009·Cancer·Fabio CalabròCora N Sternberg
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria De SantisRichard Sylvester
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntRonald de Wit
Oct 9, 2012·Seminars in Oncology·Joaquim Bellmunt, Daniel P Petrylak
Oct 23, 2012·European Urology·Mahul B AminUNKNOWN International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012
Feb 20, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BellmuntT K Choueiri
Oct 25, 2014·BMC Cancer·Daniel CastellanoEnrique Grande
Dec 3, 2014·Clinical Genitourinary Cancer·Andrea NecchiGuru Sonpavde
Apr 8, 2015·The Oncologist·Richard M BamburyJonathan E Rosenberg
Jun 11, 2016·Molecular and Clinical Oncology·Spyridon SiderisThierry Gil